Novavax, Inc. (NASDAQ: NVAX) said Tuesday afternoon it has initiated development of a vaccine candidate for the Wuhan-version of the coronavirus that has spread from China to other Asian nations and on Tuesday was confirmed to have infected at least one person in the United States. The company said it has extensive history working with coronaviruses and developing vaccine candidates, including its work on the MERS and SARS coronaviruses. “Using Novavax’ recombinant nanoparticle vaccine technology, the company expects to develop a vaccine candidate from the genetic sequence of the Wuhan coronavirus,” the company said in a statement.